Presidio snags preclinical hep C program for $108M
This is a discussion on Presidio snags preclinical hep C program for $108M within the Biotechnology News forum, part of the Industry News and Updates category; XTL Biopharmaceuticals is pocketing a $4 million upfront fee and stands to earn another $104 million in milestones after inking ...
|
|||||||
| Register | Help | Members List | Mark Forums Read |
03-20-2008, 01:28 PM
|
|||
|
|||
Presidio snags preclinical hep C program for $108M
XTL Biopharmaceuticals is pocketing a $4 million upfront fee and stands to earn another $104 million in milestones after inking a collaboration deal with
|
Linear Mode
